VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Update

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) saw a significant decrease in short interest during the month of February. As of February 13th, there was short interest totaling 1,609,597 shares, a decrease of 21.0% from the January 29th total of 2,036,211 shares. Based on an average daily trading volume, of 1,300,966 shares, the days-to-cover ratio is presently 1.2 days. Currently, 4.2% of the company’s shares are sold short. Currently, 4.2% of the company’s shares are sold short. Based on an average daily trading volume, of 1,300,966 shares, the days-to-cover ratio is presently 1.2 days.

VistaGen Therapeutics Price Performance

VTGN opened at $0.59 on Monday. The business has a 50 day simple moving average of $0.62 and a 200-day simple moving average of $2.64. The stock has a market capitalization of $23.22 million, a P/E ratio of -0.31 and a beta of 0.29. VistaGen Therapeutics has a 12 month low of $0.43 and a 12 month high of $5.14.

VistaGen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings data on Thursday, February 12th. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.06. The business had revenue of $0.30 million for the quarter, compared to analyst estimates of $0.14 million. Research analysts anticipate that VistaGen Therapeutics will post -1.77 EPS for the current year.

Institutional Trading of VistaGen Therapeutics

A number of institutional investors have recently added to or reduced their stakes in VTGN. Bank of America Corp DE grew its position in VistaGen Therapeutics by 1,068.0% during the fourth quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after buying an additional 19,331 shares during the period. Cubist Systematic Strategies LLC purchased a new position in VistaGen Therapeutics in the 1st quarter valued at approximately $25,000. Marshall Wace LLP acquired a new position in VistaGen Therapeutics during the second quarter worth $69,000. Stempoint Capital LP boosted its position in VistaGen Therapeutics by 2.0% during the second quarter. Stempoint Capital LP now owns 2,413,254 shares of the company’s stock worth $4,827,000 after purchasing an additional 46,700 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in VistaGen Therapeutics during the second quarter worth $190,000. Hedge funds and other institutional investors own 78.39% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on VTGN shares. Stifel Nicolaus cut VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 target price for the company. in a research note on Wednesday, December 17th. Maxim Group reaffirmed a “hold” rating on shares of VistaGen Therapeutics in a research report on Wednesday, December 17th. Jefferies Financial Group reiterated a “hold” rating and issued a $0.90 price objective (down from $15.00) on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. William Blair reiterated a “market perform” rating on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Finally, Wall Street Zen raised shares of VistaGen Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 14th. Four equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average target price of $0.95.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.